A Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Condition:   Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Interventions:   Drug: GDC-9545;   Drug: GDC-9545-matched Placebo;   Drug: Letrozole;   Drug: Letrozole-matched Placebo;   Drug: Palbociclib;   Drug: LHRH Agonist Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials